Ming‐Hua Zheng

29.3k total citations · 8 hit papers
385 papers, 10.7k citations indexed

About

Ming‐Hua Zheng is a scholar working on Epidemiology, Hepatology and Surgery. According to data from OpenAlex, Ming‐Hua Zheng has authored 385 papers receiving a total of 10.7k indexed citations (citations by other indexed papers that have themselves been cited), including 253 papers in Epidemiology, 154 papers in Hepatology and 74 papers in Surgery. Recurrent topics in Ming‐Hua Zheng's work include Liver Disease Diagnosis and Treatment (233 papers), Liver Disease and Transplantation (76 papers) and Diet, Metabolism, and Disease (44 papers). Ming‐Hua Zheng is often cited by papers focused on Liver Disease Diagnosis and Treatment (233 papers), Liver Disease and Transplantation (76 papers) and Diet, Metabolism, and Disease (44 papers). Ming‐Hua Zheng collaborates with scholars based in China, United Kingdom and Italy. Ming‐Hua Zheng's co-authors include Giovanni Targher, Christopher D. Byrne, Joonil Jung, Kenneth S. Zaret, Keqing Shi, Kenneth I. Zheng, Mitchell Goldfarb, Yongping Chen, Yong‐Ping Chen and Wen‐Yue Liu and has published in prestigious journals such as Science, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Ming‐Hua Zheng

367 papers receiving 10.6k citations

Hit Papers

Initiation of Mammalian Liver Development from Endoderm b... 1999 2026 2008 2017 1999 2024 2022 2020 2023 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Initiation of Mammalian Liver Development from Endoderm by Fibroblast Growth Factors
    1999 564 citations Ming‐Hua Zheng et al. profile →
  2. Current status and future trends of the global burden of MASLD
    2024 299 citations Giovanni Targher, Ming‐Hua Zheng et al. profile →
  3. MAFLD: How is it different from NAFLD?
    2022 238 citations Ming‐Hua Zheng et al. profile →
  4. MAFLD and risk of CKD
    2020 209 citations Dan‐Qin Sun, Kenneth I. Zheng et al. profile →
  5. Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease
    2023 99 citations Luca Valenti, Vincent Wai‐Sun Wong et al. profile →
  6. The first MASH drug therapy on the horizon: Current perspectives of resmetirom
    2024 82 citations Salvatore Petta, Giovanni Targher et al. Liver International profile →
  7. Chimeric antigen receptor-modified macrophages ameliorate liver fibrosis in preclinical models
    2024 51 citations Ming‐Hua Zheng et al. Journal of Hepatology profile →
  8. The Global Burden of Cirrhosis and Other Chronic Liver Diseases in 2021
    2025 13 citations Ming‐Hua Zheng et al. Liver International profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ming‐Hua Zheng China 55 5.1k 3.3k 2.7k 2.6k 1.6k 385 10.7k
Jung‐Hwan Yoon South Korea 59 6.7k 1.3× 6.8k 2.1× 2.8k 1.0× 2.8k 1.1× 1.3k 0.8× 425 13.6k
Elizabeth E. Powell Australia 49 9.3k 1.8× 6.6k 2.0× 1.8k 0.7× 1.9k 0.8× 2.5k 1.5× 213 13.8k
Frank Lammert Germany 65 6.6k 1.3× 5.3k 1.6× 1.9k 0.7× 5.4k 2.1× 1.0k 0.6× 514 15.3k
Jacob George Australia 52 11.6k 2.3× 6.4k 2.0× 2.0k 0.8× 1.9k 0.7× 4.1k 2.5× 275 15.4k
Tom Luedde Germany 65 6.6k 1.3× 5.0k 1.5× 5.4k 2.0× 2.5k 1.0× 800 0.5× 377 18.5k
Daniel Q. Huang Singapore 35 4.8k 0.9× 2.8k 0.9× 1.0k 0.4× 748 0.3× 1.3k 0.8× 180 7.1k
Jeong‐Hoon Lee South Korea 42 4.2k 0.8× 4.1k 1.2× 1.4k 0.5× 1.5k 0.6× 735 0.5× 370 8.4k
Javier Crespo Spain 39 3.7k 0.7× 2.3k 0.7× 1.4k 0.5× 932 0.4× 669 0.4× 365 7.1k
Yi‐Hsiang Huang Taiwan 49 5.9k 1.1× 7.4k 2.3× 1.2k 0.4× 1.9k 0.7× 370 0.2× 528 10.8k
Shou‐Dong Lee Taiwan 56 8.0k 1.6× 8.9k 2.7× 1.7k 0.6× 3.4k 1.3× 394 0.2× 462 14.2k

Countries citing papers authored by Ming‐Hua Zheng

Since Specialization
Citations

This map shows the geographic impact of Ming‐Hua Zheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ming‐Hua Zheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ming‐Hua Zheng more than expected).

Fields of papers citing papers by Ming‐Hua Zheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ming‐Hua Zheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ming‐Hua Zheng. The network helps show where Ming‐Hua Zheng may publish in the future.

Co-authorship network of co-authors of Ming‐Hua Zheng

This figure shows the co-authorship network connecting the top 25 collaborators of Ming‐Hua Zheng. A scholar is included among the top collaborators of Ming‐Hua Zheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ming‐Hua Zheng. Ming‐Hua Zheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Hanyang, Sander Lefere, Adrien Guillot, Ming‐Hua Zheng, & Frank Tacke. (2025). Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): Current knowledge of mechanisms. Hepatology. 2 indexed citations
2.
Lonardo, Amedeo, et al.. (2025). MASLD vs. MAFLD. A narrative review. SHILAP Revista de lepidopterología. 4. 1 indexed citations
3.
Wang, Luyao, Lei Fan, Hongru Kong, et al.. (2025). Repression of the ERRγ-CYP2E1 pathway by FGF4 mitigates alcohol-associated liver injury. Hepatology. 82(5). 1138–1154.
4.
Ye, Junzhao, Jiaming Lai, Xiaodong Zhuang, et al.. (2025). Machine Learning Models for Screening Steatosis in MASLD : An International Validation Study. Liver International. 45(12). e70416–e70416.
5.
Lam, Sin Man, Zehua Wang, Jin‐Wen Song, et al.. (2024). Non-invasive lipid panel of MASLD fibrosis transition underscores the role of lipoprotein sulfatides in hepatic immunomodulation. Cell Metabolism. 37(1). 69–86.e7. 8 indexed citations
6.
Lu, Jie, Yuejun Liu, Ni Zhang, et al.. (2024). Improvement of MASLD and MASH by suppression of hepatic N-acetyltransferase 10. Molecular Metabolism. 89. 102030–102030. 7 indexed citations
7.
8.
Yang, Xinquan, Chaodong Ge, Wenjian He, et al.. (2024). Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASH. Cell Metabolism. 36(10). 2190–2206.e5. 36 indexed citations
9.
Fouad, Yasser, Mohamed Alboraie, Ahmed Gomaa, Ming‐Hua Zheng, & Amedeo Lonardo. (2024). Could controversies in the arena of fatty liver disease be a potential gate for the democratization of science. 4(3). 1 indexed citations
10.
Luo, Shan, Ming‐Hua Zheng, Vincent Wai‐Sun Wong, & Shiu Lun Au Yeung. (2024). Drug-target Mendelian randomisation applied to metabolic dysfunction-associated steatotic liver disease: opportunities and challenges. SHILAP Revista de lepidopterología. 2(4). e100114–e100114. 4 indexed citations
11.
Sun, Dan‐Qin, Jiaqi Shen, Yangyang Li, et al.. (2024). FRI-267 Regional fibrosis progression analysed by digital pathology with artificial intelligence is associated with renal dysfunction. Journal of Hepatology. 80. S488–S489. 1 indexed citations
12.
Petta, Salvatore, Giovanni Targher, Stefano Romeo, et al.. (2024). The first MASH drug therapy on the horizon: Current perspectives of resmetirom. Liver International. 44(7). 1526–1536. 82 indexed citations breakdown →
13.
Yang, Xueyan, Yu‐Xin Tian, Feng Jin, et al.. (2024). Dose-dependent Relationship between Alcohol Consumption and the Risks of Hepatitis B Virus-associated Cirrhosis and Hepatocellular Carcinoma: A Meta-analysis and Systematic Review. Journal of Clinical and Translational Hepatology. 0(0). 0–0. 2 indexed citations
14.
Pan, Chuyue, Jun Liu, Yingsheng Gao, et al.. (2023). Hepatocyte CHRNA4 mediates the MASH-promotive effects of immune cell-produced acetylcholine and smoking exposure in mice and humans. Cell Metabolism. 35(12). 2231–2249.e7. 11 indexed citations
15.
Ma, Hong‐Lei, Kenneth I. Zheng, Rafael S. Rios, et al.. (2021). Histological Characteristics of Non-alcoholic Steatohepatitis in NAFLD Patients With Low Degree of Hepatocyte Apoptosis. The Turkish Journal of Gastroenterology. 32(9). 758–764. 1 indexed citations
16.
Zheng, Kenneth I., Xiaobo Wang, Huadong Yan, et al.. (2020). Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients. Journal of Gastroenterology and Hepatology. 36(1). 204–207. 89 indexed citations
17.
Zheng, Ming‐Hua, Wei Sun, Jingyi Jin, & Chun‐Hua Yan. (2014). Molecular Keypad Locks Based on Gated Photochromism and Enhanced Fluorescence by Protonation Effects. Journal of Fluorescence. 24(4). 1169–1176. 19 indexed citations
18.
Fan, Yu‐Chen, et al.. (2013). Emerging Role of Interleukin 22 in Hepatitis B Virus Infection: a Double-edged Sword. Journal of Clinical and Translational Hepatology. 1(2). 103–8. 15 indexed citations
19.
Zhong, Bao‐Liang, et al.. (2009). The Quality of Randomized Controlled Trials on DanShen in the Treatment of Ischemic Vascular Disease. The Journal of Alternative and Complementary Medicine. 15(5). 557–565. 10 indexed citations
20.
Meng, Maobin, Yao‐Li Cui, Yong‐Song Guan, et al.. (2008). Traditional Chinese Medicine Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma. The Journal of Alternative and Complementary Medicine. 14(8). 1027–1042. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jung‐Hwan Yoon Breakdown of academic impact, for papers by Elizabeth E. Powell Breakdown of academic impact, for papers by Frank Lammert Breakdown of academic impact, for papers by Jacob George Breakdown of academic impact, for papers by Tom Luedde Breakdown of academic impact, for papers by Daniel Q. Huang Breakdown of academic impact, for papers by Jeong‐Hoon Lee Breakdown of academic impact, for papers by Javier Crespo Breakdown of academic impact, for papers by Yi‐Hsiang Huang Breakdown of academic impact, for papers by Shou‐Dong Lee
Rankless by CCL
2026